Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM7 | Q14831 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | SLC5A7 | Q9GZV3 | 3/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.33 |
| ▸ | PDE4A | P27815 | 2/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29620700 | 1.00 | GRM7 (0.35) | GRM7MEN1KMT2ASLC5A7TDP1 | |
| SCHEMBL24345696 | 1.00 | GRM7 (0.35) | GRM7MEN1KMT2ASLC5A7TDP1 | |
| SCHEMBL29620718 | 0.93 | GRM7 (0.35) | GRM7MEN1KMT2ASLC5A7TDP1 | |
| SCHEMBL24345701 | 0.93 | GRM7 (0.35) | GRM7MEN1KMT2ASLC5A7TDP1 | |
| SCHEMBL24345709 | 0.93 | GRM7 (0.36) | GRM7MEN1KMT2ASLC5A7TDP1 | |
| SCHEMBL29620729 | 0.93 | GRM7 (0.36) | GRM7MEN1KMT2ASLC5A7TDP1 | |
| SCHEMBL24345280 | 0.93 | GRM7 (0.36) | GRM7MEN1KMT2ASLC5A7TDP1 | |
| SCHEMBL24345313 | 0.91 | SLC5A7 (0.36) | GRM7MEN1KMT2ASLC5A7TDP1 | |
| SCHEMBL24345312 | 0.91 | SLC5A7 (0.36) | GRM7MEN1KMT2ASLC5A7TDP1 | |
| SCHEMBL23700528 | 0.88 | EPHX2 (0.35) | GRM7MEN1KMT2ASLC5A7TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119398-A1 | HETEROCYCLIC COMPOUNDS AS ANTI-VIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119398-A1 | HETEROCYCLIC COMPOUNDS AS ANTI-VIRAL AGENTS | VIP, ACE, FURIN | GRM7 3960/4885MEN1 1492/4885KMT2A 2438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.